CHMP recommends EU approval of Roche ’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
If approved, Alecensa will be the first and only ALK inhibitor approved for people with resected ALK-positive early-stage non-small cell lung cancer (NSCLC)The positive recommendation is based on results from the Phase III ALINA study where Alecensa showed an unprecedented 76% reduction in the risk of disease recurrence or death, compared to adjuvant chemotherapy1With about half of people living with early-stage NSCLC experiencing disease recurrence or death following surgery, Alecensa could minimise the risk by treating NSCLC before it has spread2Basel, 26 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today th...
Source: Roche Investor Update - April 26, 2024 Category: Pharmaceuticals Source Type: news
Guidelines Don ’t Eliminate Variations in Chemotherapy Uptake Guidelines Don ’t Eliminate Variations in Chemotherapy Uptake
Prof David Kerr discusses the disconnect between national and international guidelines and variations in chemotherapy uptake.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
‘Real hope’ for cancer cure as personal mRNA vaccine for melanoma trialled
Excitement among patients and researchers as custom-built jabs enter phase 3 trialDoctors have begun trialling in hundreds of patients the world ’s first personalised mRNA cancer vaccine for melanoma, as experts hailed its “gamechanging” potential to permanently cure cancer.Melanoma affects about 132,000 people a year globally and is the biggest skin cancer killer. Currently, surgery is the main treatment although radiotherapy, medicines and chemotherapy are also sometimes used.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 26, 2024 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer Skin cancer Drugs Medical research Science Health Vaccines and immunisation UK news UCL (University College London) Source Type: news
Promising perspectives for the application of SDS Optic's inPROBE technology platform for protein expression determination
LUBLIN, Poland, April 25, 2024 (GLOBE NEWSWIRE) -- An inherent feature of oncology is personalization, i.e., conversion from the fit-to-all strategy based on applying the same chemotherapy regimens to all patients with a specific type of cancer to therapy individually tailored to the patient.…#lublin #poland #ihc #fish #inprobe (Source: Reuters: Health)
Source: Reuters: Health - April 25, 2024 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Investor Update - April 24, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Media News - April 24, 2024 Category: Pharmaceuticals Source Type: news
The Internet Has Made Health Anxiety Worse Than Ever
“Don’t google your cancer,” the oncology nurse said to me as she drew my blood ahead of my first round of chemotherapy. It was 2006 and I was 17 years old. I was very confused by the emphasis she put on this advice. Still, I took the print-out of “safe” web addresses she gave me home and pinned it on the noticeboard in the kitchen, where it stayed, ignored, as I slowly progressed through six months of cancer treatment.
[time-brightcove not-tgx=”true”]
I was confused because the opportunities for me to use the internet to research my recent diagnosis of Hodgkin’s Lymphoma,...
Source: TIME: Health - April 24, 2024 Category: Consumer Health News Authors: Caroline Crampton Tags: Uncategorized freelance Source Type: news
‘Kinder’ treatment for childhood brain cancer to be offered by NHS in England
Dabrafenib with trametinib can halt growth of some tumours for more than three times as long as standard chemotherapy, study showsThe NHS is to offer children with brain tumours in England a groundbreaking new targeted drug therapy to tackle the disease – a development charities are hailing as the biggest breakthrough in decades.Gliomas are the most common type of brain cancer in children but experts say the standard treatment of chemotherapy can be brutal and gruelling, and also carries the risk of side-effects such as weight loss, seizures and headaches.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 24, 2024 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer Children's health National Institute for Health and Care Excellence England NHS UK news Society Medical research Science Source Type: news
Is Osimertinib Better Alone or With Chemotherapy in NSCLC? Is Osimertinib Better Alone or With Chemotherapy in NSCLC?
A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Media News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Tumor-Infiltrating Lymphocyte Abundance Prognostic in Early-Stage TNBC
THURSDAY, April 18, 2024 -- For patients with early-stage triple-negative breast cancer (TNBC) who undergo surgery without chemotherapy, tumor-infiltrating lymphocyte (TIL) abundance is associated with improved survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2024 Category: Pharmaceuticals Source Type: news
Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity
The PROACT trial assessing enalapril in patients with cancer undergoing chemotherapy showed this approach did not affect cardiac function or the rate of cardiac injury.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 18, 2024 Category: Internal Medicine Tags: Cardiology News Source Type: news
Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant
WEDNESDAY, April 17, 2024 -- Bilateral Wilms tumors (BWTs) that increase in size during neoadjuvant chemotherapy, especially in younger patients, are most often stromal-predominant, according to a study published online March 27 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2024 Category: Pharmaceuticals Source Type: news
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca Plc AZN released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in combination with standard-of-care chemotherapy for advanced biliary tract cancer (BTC). The data showed that Imfinzi plus standard-of-care chemotherapy demonstrated a clinically…#astrazenecaplcazn #topaz1phase3 #imfinzi #topaz1 #median #azn (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2024 Category: Consumer Health News Source Type: news
